BioSpace News Archive

Eterna Therapeutics Inc., a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, announced the appointment of Jeff Karp, Ph.D. to Eterna’s Scientific Advisory Board.

Cryoport, Inc., a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry and a leader in supply chain solutions for the reproductive medicine markets, announced a multi-year agreement with Inception Fertility™, North America’s largest provider of comprehensive fertility services.

Lantern Pharma Inc. today announced the dosing of the first patient in the Phase 2 Harmonic™ clinical trial evaluating Lantern’s investigational new drug LP-300.

Compass Therapeutics, Inc. (Nasdaq: CMPX) today announced that the Company will participate in the Cantor Fitzgerald Future of Oncology Symposium, which is taking place virtually on April 3 – 5, 2023.

SQI Diagnostics Inc., a leader in the science of lung health, announced that it is moving to strategically focus on what is now its core business: creating precision Point of Care products in respiratory health.

Mustang Bio, Inc. today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in Cantor’s The Future of Oncology Virtual Symposium.

Morphogenesis Inc., a Phase 3 clinical stage biopharmaceutical company developing novel personalized cancer vaccines, announced today that it has entered into a definitive asset purchase agreement, in a stock for stock transaction, to acquire TυHURA’s novel ADCs targeting MDSCs to modulate tumor microenvironment immunosuppression.

TrueBinding, Inc.— a clinical-stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and other disease areas with great unmet needs— today announced early results from an Open-Label Extension (OLE) study for the use of its TB006 drug in the treatment of Alzheimer’s Disease.

RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”) is pleased to announce that on March 22, 2023, Mr. Joseph Siegelbaum was appointed to the Board of Directors as an independent director.

ThermoGenesis Holdings, Inc. today announced that the Company will release its financial results for the year ended December 31, 2022 and provide a corporate strategic update on Thursday, March 30, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET.